Mechanisms of the Action of Zoledronic Acid on Human MG-63 Osteosarcoma Cells

Abstract

The aim of our study was to analyze the action of zoledronic acid on MG-63 human osteosarcoma cells. The proliferation of MG-63 cells was inhibited by either continuous or pulsatile exposures of zoledronic acid in a dose-dependent manner (10–250 μM). Zoledronic acid did not produce evidence of MG-63 cell death when administered at 100 mM for 48 hours, but only after exposure of 96 hours. Zoledronic acid (100 μM) increased the distribution of MG-63 cells in G0/G1 phase, however, it did not increase the adriamycin-induced apoptosis. In addition, zoledronic acid action was partially neutralized by exogenous administration of geranylgeranyl pyrophosphate (GGPP), but not by farnesyl pyrophosphate (FPP). Furthermore, zoledronic acid resulted in the attenuation of the prenylated form of Ras. Zoledronic acid and EDTA increased fluorescence of Fluo-3 loaded MG-63 cells in a similar pattern. This increase was owing to the release of Ca²⁺from intracellular stores since zoledronic acid failed to reveal such a change to intracellular Ca²⁺when cells were previously treated with 1 mM caffeine. Moreover, zoledronic acid significantly decreased the expression of estrogen receptor α (ERα) whereas it did not change significantly the expression of estrogen receptor β (ERβ) in MG-63 cells. These data suggest that zoledronic acid can control the proliferation and the differentiation of osteosarcoma-like cells.

MG-63 cells - zoledronic acid - Ras - calcium - estrogen receptors

References

• 1 Ferrari S, Bertoni F, Mercuri M. et al . Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.  Ann Oncol. 2001;  12 1145-1150
• 2 Bacci G, Ferrari S, Delepine N. et al . Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.  J Clin Oncol. 1998;  16 658-663
• 3 Rodriguez-Galindo C, Shah N, MacCarville MB. et al . Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970–2000).  Cancer. 2004;  100 1928-1935
• 4 Bacci G, Ferrari S, Longhi A. et al . High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.  J Chemother. 2002;  14 198-206
• 5 Bacci G, Ferrari S, Lari S. et al . Osteosarcoma of the limb. Amputa-tion or limb salvage in patients treated by neoadjuvant chemotherapy.  J Bone Joint Surg Br. 2002;  84 88-92
• 6 Bacci G, Ferrari S, Longhi A. et al . Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.  J Chemother. 2001;  13 93-99
• 7 Patel SR, Papadopolous N, Raymond AK. et al . A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.  Cancer. 2004;  101 156-163
• 8 Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.  Cancer Res. 2005;  65 4971-4974
• 9 Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status.  Clin Cancer Res. 2006;  12 6222s-6230s
• 10 Aubin JE, Liu F, Malaval L, Gupta AK. Osteoblast and chondroblast differentiation.  Bone. 1995;  17 77S-83S
• 11 Cao L, Bu R, Oakley JI, Kalla SE, Blair HC. Estrogen receptor-beta modulates synthesis of bone matrix proteins in human osteoblast-like MG63 cells.  J Cell Biochem. 2003;  89 152-164
• 12 Monroe DG, Getz BJ, Johnsen SA. et al . Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta.  J Cell Biochem. 2003;  90 315-326
• 13 Vistica DT, Skehan P, Scudiero D. et al . Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production.  Cancer Res. 1991;  51 2515-2520
• 14 Dimolea E, Tiniakos D, Pechtelidou A, Florentin I, Kittas C, Sekeris C, Alexis M. Production and characterization of antibodies to estrogen receptor-beta isoforms effective for use on routinely-processed human tissues.  Virchows Arch. 2005;  447 490
• 15 Saad F, Gleason DM, Murray R. et al . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.  J Natl Cancer Inst. 2002;  94 1458-1468
• 16 Ibrahim A, Scher N, Williams G. et al . Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.  Clin Cancer Res. 2003;  9 2394-2399
• 17 Mundy GR. Bisphosphonates as cancer drugs.  Hosp Pract (Off Ed). 1999;  34 81-84 , , 88–89, 93–94
• 18 Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.  J Urol. 2003;  170 246-252
• 19 Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.  Cancer Res. 2002;  62 2708-2714
• 20 Tenta R, Tiblalexi D, Sotiriou E. et al . Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells.  Prostate. 2004;  59 120-131
• 21 Sonnemann J, Eckervogt V, Truckenbrod B. et al . The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.  Anticancer Drugs. 2001;  12 459-465
• 22 Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.  Bone. 2003;  33 216-228
• 23 Kanakis I, Kousidou O, Karamanos NK. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.  In Vivo. 2005;  19 311-318
• 24 Koutsilieris M, Mitsiades C, Sourla A. Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer.  Mol Med. 2000;  6 251-267
• 25 Reinholz GG, Getz B, Sanders ES. et al . Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.  Breast Cancer Res Treat. 2002;  71 257-268
• 26 Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.  Cell. 1994;  77 175-178
• 27 Lobell RB, Omer CA, Abrams MT. et al . Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.  Cancer Res. 2001;  61 8758-8768
• 28 Macchia M, Jannitti N, Gervasi G, Danesi R. Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins.  J Med Chem. 1996;  39 1352-1356
• 29 Tassone P, Tagliaferri P, Viscomi C. et al . Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.  Br J Cancer. 2003;  88 1971-1978
• 30 Luckman SP, Hughes DE, Coxon FP. et al . Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.  J Bone Miner Res. 1998;  13 581-589
• 31 Koshimune R, Aoe M, Toyooka S. et al . Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.  BMC Cancer. 2007;  7 8
• 32 Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates.  Biomaterials. 2004;  25 4105-4115
• 33 Pan B, To LB, Farrugia AN. et al . The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro.  Bone. 2004;  34 112-123
• 34 Monroe DG, Johnsen SA, Subramaniam M. et al . Mutual antagonism of estrogen receptors alpha and beta and their preferred interac-tions with steroid receptor coactivators in human osteoblastic cell lines.  J Endocrinol. 2003;  176 349-357
• 35 Stossi F, Barnett DH, Frasor J. et al . Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors.  Endocrinology. 2004;  145 3473-3486
• 36 Tchetina E, Mwale F, Poole AR. Distinct phases of coordinated early and late gene expression in growth plate chondrocytes in relationship to cell proliferation, matrix assembly, remodeling, and cell differentiation.  J Bone Miner Res. 2003;  18 844-851
• 37 Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.  Semin Oncol. 2001;  28 35-44
• 38 Tenta R, Sourla A, Lembessis P, Koutsilieris M. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH. 1 receptor bioregulation systems in MG-63 human osteosarcoma cells.  Anticancer Res. 2006;  26 283-291
• 39 Jans DA, Thomas RJ, Gillespie MT. Parathyroid hormone-related protein (PTHrP): a nucleocytoplasmic shuttling protein with distinct paracrine and intracrine roles.  Vitam Horm. 2003;  66 345-384

Correspondence